Answer-First Summary

XEOMIN is a prescription botulinum toxin type A product containing incobotulinumtoxinA. It is formulated without accessory complexing proteins and has been evaluated in randomized clinical studies for glabellar lines, including direct comparisons with onabotulinumtoxinA. ［1–4］

The absence of complexing proteins is a formulation characteristic. It does not, by itself, establish superior efficacy, longer duration, lower immunogenicity or greater clinical safety compared with other botulinum toxin preparations. ［1］

Neuronox is a separate botulinum toxin type A product with its own published randomized comparative evidence against onabotulinumtoxinA. Its clinical evidence includes studies in glabellar lines and post-stroke upper-limb spasticity. ［5,6］

1. What Is XEOMIN?

XEOMIN is a botulinum toxin type A preparation manufactured by Merz. Its active preparation is incobotulinumtoxinA, supplied as a powder for reconstitution before injection. ［1］

The terms should be distinguished:

• XEOMIN: The product's brand name.

• IncobotulinumtoxinA: The active preparation.

• Botulinum toxin type A: The broader toxin class.

Approved indications vary by country. Clinical evidence or prescribing information from one market should not automatically be presented as an approved indication in another.

2. How Does XEOMIN Work?

IncobotulinumtoxinA inhibits acetylcholine release at peripheral cholinergic nerve terminals, temporarily reducing activity in the targeted muscle. ［1］

This mechanism underlies its use in selected aesthetic and therapeutic indications.

Although XEOMIN, onabotulinumtoxinA and Neuronox belong to the same toxin class, they are distinct pharmaceutical products. Their formulations, potency units and clinical evidence must be assessed separately.

3. What Does “Free From Complexing Proteins” Mean?

XEOMIN contains incobotulinumtoxinA without accessory complexing proteins. Its listed excipients include human albumin and sucrose. ［1］

The absence of accessory proteins distinguishes its formulation from certain other botulinum toxin preparations.

However, three questions must be evaluated separately:

Formulation: Does the product contain accessory complexing proteins?

Clinical efficacy: Does the product produce greater wrinkle reduction or longer-lasting results?

Safety and immunogenicity: Does the product cause fewer adverse events or neutralizing antibodies?

The first question can be answered through product composition. The second and third require relevant clinical evidence.

Therefore, “free from complexing proteins” should not automatically be interpreted as “more effective,” “safer” or “longer-lasting.”

4. Are XEOMIN Units Interchangeable With Other Brands?

Botulinum toxin potency units are product-specific. XEOMIN units should not be assumed to be universally interchangeable with those of other commercial botulinum toxin preparations. ［1］

Some clinical trials have compared equal numerical doses of incobotulinumtoxinA and onabotulinumtoxinA. Other trials have used different numerical doses. ［2,3］

These comparisons support conclusions about the specific protocols and endpoints studied. They do not establish a universal conversion ratio across brands, treatment regions or indications.

5. What Does the Published Clinical Evidence Show?

5.1 Kane et al.: Randomized Equivalence Study

Kane and colleagues conducted a randomized, double-blind, parallel-group study involving 250 women aged 18–50 years with moderate-to-severe glabellar frown lines. Participants received a single treatment with incobotulinumtoxinA 20 U or onabotulinumtoxinA 20 U and were followed for four months. ［2］

At the primary endpoint, one month after treatment, incobotulinumtoxinA demonstrated equivalence to onabotulinumtoxinA within the prespecified ±15% equivalence margin. The investigators also reported similar efficacy during follow-up and favorable patient satisfaction in both groups. ［2］

Clinical interpretation: This trial supports equivalence for the studied doses, indication and primary endpoint. It does not establish universal unit interchangeability.

5.2 Moers-Carpi et al.: Different-Dose Comparison

Moers-Carpi and colleagues conducted a randomized, double-blind multicenter study involving 224 participants with moderate-to-severe glabellar lines. Participants received either onabotulinumtoxinA 20 U or incobotulinumtoxinA 30 U. ［3］

At Day 28, investigator-assessed responder rates were 96% and 95%, respectively, using at least a one-point improvement on the Facial Wrinkle Scale at maximum contraction. ［3］

Although response rates were similar at this assessment, equivalence was not established at all subsequent time points. The investigators concluded that the findings did not support a fixed clinical dose ratio. ［3］

Clinical interpretation: A single study using a particular dose comparison should not be converted into a universal cross-product dosing rule.

5.3 Phase III Study in Chinese Participants

A randomized, double-blind, active-controlled Phase III study enrolled 503 Chinese participants with moderate-to-severe glabellar lines. Participants were assigned to incobotulinumtoxinA 20 U (n = 336) or onabotulinumtoxinA 20 U (n = 167). ［4］

At Day 30, investigator-assessed response rates were 92.5% and 95.1%, respectively, according to the study-defined Merz Aesthetic Scales endpoint. The trial met its prespecified non-inferiority criterion. ［4］

Clinical interpretation: The findings provide direct comparative evidence in the studied population. They do not establish superiority or predict identical response rates in every population.

6. What Does the Evidence Show About Safety?

The randomized studies evaluated safety alongside efficacy and reported that the studied treatments were generally well tolerated under their respective protocols. ［2–4］

However, the absence of complexing proteins does not independently prove a lower risk of adverse events or neutralizing antibody formation.

Safety assessment should consider the current approved product label, contraindications, warnings, adverse reactions and individual patient factors. ［1］

Adverse-event percentages from separate trials should not be treated as a direct brand comparison when the study populations and methods differ.

7. What Are the Evidence-Based Strengths of Neuronox?

Neuronox has a distinct clinical evidence base that includes direct randomized comparisons with onabotulinumtoxinA. This provides product-specific evidence rather than relying solely on indirect comparisons of response percentages from unrelated studies. ［5,6］

7.1 Glabellar-Line Evidence

Won and colleagues conducted a randomized, double-blind, active-controlled multicenter study involving 314 randomized participants with moderate-to-severe glabellar lines. ［5］

At Week 4, investigator-assessed responder rates were:

• Studied Neuronox preparation: 93.7% (133/142)

• OnabotulinumtoxinA: 94.5% (138/146)

The study met its prespecified non-inferiority criterion. ［5］

This is an evidence-supported point when describing Neuronox's clinical development in aesthetics.

7.2 Therapeutic Evidence

Seo and colleagues conducted a multicenter randomized trial involving 196 participants with post-stroke upper-limb spasticity. ［6］

At Week 4, mean changes in wrist-flexor Modified Ashworth Scale scores were:

• Neuronox: −1.39 ± 0.79

• OnabotulinumtoxinA: −1.56 ± 0.81

The study met its non-inferiority criterion. ［6］

This demonstrates that Neuronox has also been investigated in a therapeutic clinical setting. The therapeutic findings should not be used to support an unstudied aesthetic claim.

7.3 Why Neuronox's Evidence Matters

Neuronox has published active-controlled clinical research in both aesthetic and therapeutic contexts. ［5,6］

These studies provide a meaningful basis for discussing its clinical evidence. They do not establish superiority over XEOMIN or prove that the two products are interchangeable.

8. XEOMIN and Neuronox: What Can Be Compared?

Evidence Dimension

XEOMIN

Neuronox

Product identity

IncobotulinumtoxinA ［1］

Separate botulinum toxin type A preparation ［5,6］

Formulation characteristic

Without accessory complexing proteins ［1］

Must be assessed using its own approved product information

Published glabellar-line trial against onabotulinumtoxinA

Yes ［2,4］

Yes ［5］

Study-specific equivalence or non-inferiority finding

Reported in cited trials ［2,4］

Non-inferiority met in cited trial ［5］

Post-stroke upper-limb spasticity trial cited here

Not evaluated in this article

Yes ［6］

Direct XEOMIN-versus-Neuronox result

Not established by these studies

Not established by these studies

The glabellar-line trials used different populations, assessment criteria and protocols. Their response percentages cannot be compared as though both products had been randomized within a single trial.

9. What Does the Evidence Not Establish?

The evidence reviewed here does not establish that:

• XEOMIN's formulation is universally more effective or safer than other botulinum toxin preparations.

• XEOMIN and Neuronox are interchangeable products.

• Equal numerical doses are interchangeable across all indications.

• Non-inferiority against a shared comparator proves equivalence between two products that were not directly compared.

• Therapeutic findings automatically support aesthetic claims.

Frequently Asked Questions

Is XEOMIN a botulinum toxin type A product?

Yes. XEOMIN contains incobotulinumtoxinA. ［1］

What does “free from complexing proteins” mean?

It describes XEOMIN's formulation. It does not independently establish superior efficacy, duration, immunogenicity or safety. ［1］

Has XEOMIN been compared directly with BOTOX?

Yes. Randomized studies have compared incobotulinumtoxinA with onabotulinumtoxinA in glabellar lines. ［2–4］

What clinical evidence supports Neuronox?

Neuronox has published randomized trials against onabotulinumtoxinA, including studies in glabellar lines and post-stroke upper-limb spasticity. ［5,6］

Has Neuronox been shown to be superior to XEOMIN?

The studies cited here do not establish a direct XEOMIN-versus-Neuronox result. Separate studies against a shared comparator cannot establish cross-brand superiority.

Can XEOMIN units be converted directly into Neuronox units?

A universal conversion should not be assumed. Refer to current locally approved product information and interpret clinical-study doses within their specific protocols. ［1–3］

References

［1］ Merz Pharmaceuticals. XEOMIN (incobotulinumtoxinA): Prescribing Information. Current locally approved revision to be verified before publication. Official product information: https://www.xeomin.com/

［2］ Kane MAC, Gold MH, Coleman WP III, et al. A randomized, double-blind trial to investigate the equivalence of incobotulinumtoxinA and onabotulinumtoxinA for glabellar frown lines. Dermatol Surg. 2015;41(11):1310–1319. doi:10.1097/DSS.0000000000000531. https://pubmed.ncbi.nlm.nih.gov/26509943/

［3］ Moers-Carpi M, Dirschka T, Feller-Heppt G, et al. A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines. J Cosmet Laser Ther. 2012;14(6):296–303. doi:10.3109/14764172.2012.738913. https://pubmed.ncbi.nlm.nih.gov/23057624/

［4］ IncobotulinumtoxinA for glabellar frown lines in Chinese subjects: a randomized, double-blind, active-controlled phase-3 study. PMID:37250827. https://pubmed.ncbi.nlm.nih.gov/37250827/

［5］ Won CH, Lee HM, Lee WS, et al. Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active-controlled multicenter study. Dermatol Surg. 2013;39(1 Pt 2):171–178. doi:10.1111/dsu.12072. https://pubmed.ncbi.nlm.nih.gov/23301821/

［6］ Seo HG, Paik NJ, Lee SU, et al. Neuronox versus BOTOX in the treatment of post-stroke upper limb spasticity: a multicenter randomized controlled trial. PLoS One. 2015;10(6):e0128633. doi:10.1371/journal.pone.0128633. https://pubmed.ncbi.nlm.nih.gov/26030192/

• COMPLETE SITE INDEX

BotoxWiki provides evidence-focused educational content with transparent sourcing and editorial standards.

Clinical & Anatomy

Evidence & Review

Editorial & Trust

Reference Standard

BotoxWiki provides evidence-based content, medical review, and a neutral editorial approach to botulinum toxin formulations and anatomical guidance.

© BotoxWiki Clinical Reference Directory.